Trial Profile

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avexitide (Primary)
Indications Hypoglycaemia
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms LUCIDITY
Sponsors Amylyx Pharmaceuticals

Most Recent Events

04 Mar 2026 Status changed from recruiting to active, no longer recruiting.
06 Nov 2025 According to an Amylyx Pharmaceuticals media release, recruitment completion in this study is expected in Q1 2026 and topline data are expected in Q3 2026. The trial is enrolling at approximately 20 sites in the U.S.
13 Jul 2025 According to an Amylyx Pharmaceuticals media release, Marilyn Tan is the principal investigator of the LUCIDITY trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com